Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.
Serum levels of soluble CD163 and CXCL5 may be predictive markers for immune-related adverse events in patients with advanced melanoma treated with nivolumab: a pilot study.
复制标题
DOI：
10.18632/oncotarget.24509
复制
发表时间：
2018-03-20
期刊：
影响因子：
--
通讯作者：
Aiba S
中科院分区：
文献类型：
--
作者：
Fujimura T;Sato Y;Tanita K;Kambayashi Y;Otsuka A;Fujisawa Y;Yoshino K;Matsushita S;Funakoshi T;Hata H;Yamamoto Y;Uchi H;Nonomura Y;Tanaka R;Aoki M;Imafuku K;Okuhira H;Furudate S;Hidaka T;Aiba S
针对PD-1的抗体，如nivolumab和pembrolizumab，广泛用于治疗包括晚期黑色素瘤在内的各种癌症。抗pd -1 Ab可显著延长转移性黑色素瘤患者的生存期，与局部或全身治疗联合使用也可改善预后。尽管以抗pd -1抗体为基础的联合治疗可能对晚期黑色素瘤有效，但相关的irAEs风险是一个重要的考虑因素。因此，能够预测肿瘤恶性肿瘤是肿瘤学家非常感兴趣的。本研究的目的是评估使用血清sCD163和CXCL5水平预测nivolumab治疗的晚期黑色素瘤患者的irae的价值。为此，我们分析了46例接受纳武单抗治疗的晚期黑色素瘤患者的这些血清水平。采用免疫组织化学和免疫荧光法对肿瘤间质进行评价。我们在第0天（纳武单抗给药前）和第42天测量sCD163和CXCL5的血清水平。发生ae的患者血清sCD163绝对水平显著升高（p = 0.0018）。虽然两组血清CXCL5水平无显著差异，但CXCL5的绝对值至少可以作为血清sCD163绝对水平升高的一个支持性标志物。该研究表明，sCD163和CXCL5可能作为nivolumab治疗晚期黑色素瘤患者irae的预后生物标志物。
Antibodies against PD-1, such as nivolumab and pembrolizumab, are widely used in the treatment of various cancers including advanced melanoma. The anti-PD-1 Ab significantly prolongs survival in patients with metastatic melanoma, and its administration in combination with local or systemic therapy may also lead to improved outcomes. Although anti-PD-1 Ab-based combined therapy might be effective for the treatment of advanced melanoma, the associated risk of irAEs is an important consideration. Therefore, being able to predict irAEs is of great interest to oncologists. The purpose of this study was to evaluate the value of using serum levels of sCD163 and CXCL5 to predict irAEs in patients with advanced melanoma who were administered nivolumab. To this end, we analyzed these serum levels in 46 cases of advanced melanoma treated with nivolumab. In addition, the tumor stroma was evaluated by immunohistochemistry and immunofluorescence. We measured the serum levels of sCD163 and CXCL5 on day 0 (immediately before nivolumab administration) and day 42. The serum absolute levels of sCD163 were significantly increased in patients who developed AEs (p = 0.0018). Although there was no significant difference in serum levels of CXCL5, the absolute value of CXCL5 could at least be a supportive marker for the increased absolute levels of serum sCD163. This study suggests that sCD163 and CXCL5 may serve as possible prognostic biomarkers for irAEs in patients with advanced melanoma treated with nivolumab.